[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cue Biopharma Inc (CUE)

Cue Biopharma Inc (CUE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 98,546
  • Shares Outstanding, K 3,240
  • Annual Sales, $ 27,470 K
  • Annual Income, $ -26,600 K
  • EBIT $ -27 M
  • EBITDA $ -26 M
  • 60-Month Beta 2.37
  • Price/Sales 1.74
  • Price/Cash Flow N/A
  • Price/Book 1.46

Options Overview Details

View History
  • Implied Volatility 0.00% (unch)
  • Historical Volatility 364.42%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 1,001.63% on 04/06/26
  • IV Low 0.00% on 05/04/26
  • Expected Move (DTE 11) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.08
  • Today's Volume 337
  • Volume Avg (30-Day) 728
  • Put/Call OI Ratio 0.10
  • Today's Open Interest 7,025
  • Open Int (30-Day) 5,070
  • Expected Range 21.80 to 21.80

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year $-5.11
  • Growth Rate Est. (year over year) +19,649.90%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.97 +500.48%
on 04/06/26
38.00 -21.45%
on 05/01/26
+24.45 (+453.08%)
since 04/02/26
3-Month
4.97 +500.48%
on 04/06/26
38.00 -21.45%
on 05/01/26
+20.57 (+221.80%)
since 02/04/26
52-Week
4.97 +500.48%
on 04/06/26
38.00 -21.45%
on 05/01/26
+7.27 (+32.21%)
since 05/02/25

Most Recent Stories

More News
Cue Biopharma Announces $30 Million Private Placement

BOSTON, April 30, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate...

CUE : 29.85 (-1.87%)
Cue Biopharma Expands Pipeline with Exclusive License from Ascendant Health Sciences Ltd. for Clinical-Stage Dual-Mechanism Anti-IgE Antibody

Novel dual-mechanism anti-IgE antibody designed to improve upon existing and emerging therapies for IgE-mediated diseases Cue Biopharma plans to initiate global Phase 2b trial in food allergy following...

CUE : 29.85 (-1.87%)
Cue Biopharma Names Shao-Lee Lin M.D., Ph.D., CEO, President and Board Director to Lead Continued Growth and Transformation into a Clinical-Stage Company

BOSTON, April 30, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.  (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and...

CUE : 29.85 (-1.87%)
Cue Biopharma Announces 1-for-30 Reverse Stock Split

BOSTON, April 22, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.  (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and...

CUE : 29.85 (-1.87%)
Cue Biopharma to Present New Preclinical Data on Lead Autoimmune and Inflammatory Disease Candidate CUE-401 at IMMUNOLOGY2026

BOSTON, April 15, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.  (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and...

CUE : 29.85 (-1.87%)
Cue Biopharma to Receive $7.5 Million Preclinical Milestone Payment from Boehringer Ingelheim Collaboration and License Agreement

Preclinical milestone for selection and approval of first compound for lead optimization has been achieved Further development validates the potential intended mechanistic effect of CUE-501 for T cell-mediated...

CUE : 29.85 (-1.87%)
Cue Biopharma Announces CEO Transition

BOSTON, March 27, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.  (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and...

CUE : 29.85 (-1.87%)
Cue Biopharma to Host Virtual R&D Day Event on April 7, 2026

Virtual Event will feature Key Opinion Leaders (KOLs)  Richard DiPaolo, PhD, and Jonathan Kay, MD, FACP, MACR Cue Biopharma management and KOLs will discuss CUE-401, the company’s lead asset...

CUE : 29.85 (-1.87%)
Cue Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Advanced research and development of CUE-401 for IND (Investigational New Drug) readiness – CUE-401 is the Company’s lead asset for the treatment of autoimmune and inflammatory diseases Appointed...

CUE : 29.85 (-1.87%)
Cue Biopharma to Present New In vitro Data for CUE-401 at the 20th World Immune Regulation Meeting (WIRM) 2026

BOSTON, March 09, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.  (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and...

CUE : 29.85 (-1.87%)

Business Summary

Cue Biopharma, Inc. is an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. Cue Biopharma, Inc. is headquartered in Cambridge, Massachusetts.

See More

Key Turning Points

3rd Resistance Point 44.23
2nd Resistance Point 40.62
1st Resistance Point 35.23
Last Price 29.85
1st Support Level 26.23
2nd Support Level 22.62
3rd Support Level 17.23

See More

52-Week High 38.00
Last Price 29.85
Fibonacci 61.8% 25.38
Fibonacci 50% 21.49
Fibonacci 38.2% 17.59
52-Week Low 4.97

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.